Alabama Bill Would Restrict Hemp Products to In-State, Lab-Tested Sales in Certified Pharmacies

Hemp gummies.

Senate Bill 1, filed ahead of the session’s January 13 start and referred to the Senate Committee on Healthcare, targets nonpsychoactive hemp compounds like CBD, creating new rules for testing, tracking, and retail. The bill would amend current law to explicitly define only nonpsychoactive cannabinoids from hemp—such as CBD and CBG—as exempt from Alabama’s Schedule I controlled substances list. In contrast, psychoactive compounds like delta-8, delta-9, and delta-10 THC, even if derived from hemp, would be classified as controlled substances.

Under the proposed legislation, consumable hemp products could only be sold in licensed pharmacies certified by the Alabama State Board of Pharmacy. That certification would require annual renewal, product testing, and site inspections. All consumable hemp products would need to be tested in ISO-accredited labs, with detailed analysis covering potency, contaminants, and cannabinoid content. Certificates of analysis would be mandatory for all products sold.

Additionally, SB 1 would require that hemp used in consumable products be cultivated solely within Alabama. To enforce this, the Department of Agriculture and Industries would be tasked with developing a comprehensive seed-to-sale tracking system, allowing full oversight from cultivation through retail sale.

The bill also repeals provisions enacted in the 2025 session under Act 2025-385, which had previously granted regulatory authority to the Alabama Alcoholic Beverage Control Board over hemp retailers. Instead, SB 1 shifts that oversight to the State Board of Pharmacy and the Department of Agriculture and Industries.

If passed, the bill would take effect immediately.